All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

BioCryst (BCRX) Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units covering an aggregate of ...

As previously reported, Wedbush initiated coverage of BioCryst (BCRX) with an Outperform rating and $15 price target The hereditary angioedema therapeutic market represents a unique orphan disease ...

BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net ...

BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies ...

BCRX opened at $7.54 on Friday. The stock’s fifty day moving average is $8.15 and its 200-day moving average is $7.86. The company has a market capitalization of $1.58 billion, a PE ratio of -12 ...

BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50. BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last posted its earnings results on Monday, February 24th.

There's been a notable change in appetite for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares in the week since its annual report, with the stock down 12% to US$8.28. It was a pretty bad ...

Orladeyo, BioCryst’s oral treatment for HAE, has been the cornerstone of the company’s recent success. The drug has shown impressive sales growth, with full-year 2024 sales reaching $437 ...

RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors ...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Inc., a $1.54 billion market cap company with 36% revenue growth in the last twelve months, has initiated a patent infringement lawsuit to defend its drug ...